Borato D C K, Parabocz G C, Ribas J T, Netto H P, Erdmann F C, Wiecheteck L D, Manente F A, Mello L R de Almeida, Belló C, dos Santos F André, Borba L M, Vellosa J C R
Department of Clinical and Toxicological Analysis, State University of Ponta Grossa - UEPG, Uvaranas Campus, Ponta Grossa - PR, Brazil.
Department of Dentistry, State University of Ponta Grossa - UEPG, Uvaranas Campus, Ponta Grossa - PR, Brazil.
Exp Clin Endocrinol Diabetes. 2016 Jan;124(1):49-54. doi: 10.1055/s-0035-1565093. Epub 2016 Jan 21.
Chronic low-grade inflammation, combined with traditional cardiovascular risk factors, is common in obesity, providing systemic inflammation that is associated with increased cardiovascular risk. Studies have shown serum mieloperoxidase as a potential biomarker and its clinical applicability for evaluating cardiovascular risk. This study aimed to evaluate the MPO in obese individuals, with or without systemic inflammation and potential cardiovascular risk, as well as correlating MPO with some classic cardiovascular risk parameters.
Inflammatory and cardiovascular risk markers, as well as different biochemical and hematological laboratory parameters, were analyzed. The volunteers were divided into 3 groups according to the presence (hs-CRP>3 mg/L) or absence (hs-CRP<3 mg/L) of systemic inflammation and possible cardiovascular risk.
MPO was significantly increased (p<0.05) in the obese individuals with systemic inflammation. A significant increase (p<0.05) in the following biochemical parameters: glucose, HbA1c, triglycerides, non-HDL, TG/HDL was observed, and a significant decrease (p<0.01) in HDL was observed. Significant increases in the counts of total leukocytes, neutrophils and monocytes (p<0.01), as well as elevated blood pressure (p<0.05), were observed in the group of obese individuals with systemic inflammation. Serum MPO levels were correlated with classic proinflammatory and cardiovascular risk parameters.
High serum levels of MPO were observed in obese individuals with hs-CRP above 3 mg/L, which is a classic biomarker for inflammation and cardiovascular risk, suggesting the potential role of MPO in clinical applicability for cardiovascular disease in this population. However, considering that inflammation in obesity appears to manifest as a non-classical mechanism, further studies are necessary to elucidate the role of MPO in cardiovascular events in the population with obesity.
慢性低度炎症与传统心血管危险因素并存,在肥胖症中很常见,会引发全身炎症,而这与心血管风险增加相关。研究表明,血清髓过氧化物酶是一种潜在的生物标志物,且具有评估心血管风险的临床适用性。本研究旨在评估肥胖个体中髓过氧化物酶(MPO)的情况,无论其是否存在全身炎症和潜在心血管风险,同时将MPO与一些经典心血管风险参数进行关联分析。
对炎症和心血管风险标志物以及不同的生化和血液学实验室参数进行分析。根据是否存在全身炎症及可能的心血管风险(高敏C反应蛋白[hs-CRP]>3mg/L为存在,hs-CRP<3mg/L为不存在),将志愿者分为3组。
存在全身炎症的肥胖个体中MPO显著升高(p<0.05)。观察到以下生化参数显著升高(p<0.05):血糖、糖化血红蛋白、甘油三酯、非高密度脂蛋白、甘油三酯/高密度脂蛋白,同时高密度脂蛋白显著降低(p<0.01)。存在全身炎症的肥胖个体组中,总白细胞、中性粒细胞和单核细胞计数显著增加(p<0.01),血压也升高(p<0.05)。血清MPO水平与经典促炎和心血管风险参数相关。
在hs-CRP高于3mg/L的肥胖个体中观察到血清MPO水平较高,hs-CRP是炎症和心血管风险的经典生物标志物,这表明MPO在该人群心血管疾病临床适用性方面具有潜在作用。然而,鉴于肥胖中的炎症似乎表现为一种非经典机制,有必要进一步研究以阐明MPO在肥胖人群心血管事件中的作用。